DE10199054I2 - Hypoglycenisches Agens - Google Patents

Hypoglycenisches Agens

Info

Publication number
DE10199054I2
DE10199054I2 DE2001199054 DE10199054C DE10199054I2 DE 10199054 I2 DE10199054 I2 DE 10199054I2 DE 2001199054 DE2001199054 DE 2001199054 DE 10199054 C DE10199054 C DE 10199054C DE 10199054 I2 DE10199054 I2 DE 10199054I2
Authority
DE
Germany
Prior art keywords
hypoglycene
agent
hypoglycene agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2001199054
Other languages
German (de)
English (en)
Other versions
DE10199054I1 (de
Inventor
Shigeshi Toyoshima
Yoshiko Seto
Hisashi Shinkai
Koji Toi
Izumi Kumashiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of DE10199054I1 publication Critical patent/DE10199054I1/de
Application granted granted Critical
Publication of DE10199054I2 publication Critical patent/DE10199054I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2001199054 1985-03-27 1986-03-26 Hypoglycenisches Agens Active DE10199054I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6227685 1985-03-27

Publications (2)

Publication Number Publication Date
DE10199054I1 DE10199054I1 (de) 2002-01-10
DE10199054I2 true DE10199054I2 (de) 2006-04-27

Family

ID=13195452

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2001199054 Active DE10199054I2 (de) 1985-03-27 1986-03-26 Hypoglycenisches Agens
DE8686302217T Expired - Lifetime DE3683662D1 (de) 1985-03-27 1986-03-26 Hypoglycemisches agens.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8686302217T Expired - Lifetime DE3683662D1 (de) 1985-03-27 1986-03-26 Hypoglycemisches agens.

Country Status (4)

Country Link
US (2) US4816484A (enExample)
EP (1) EP0196222B1 (enExample)
JP (1) JPS6354321A (enExample)
DE (2) DE10199054I2 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2501432Y2 (ja) * 1990-01-23 1996-06-19 ヤンマー農機株式会社 移植機における苗植え間隔検出装置
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE10199058I2 (de) * 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5466864A (en) * 1993-02-25 1995-11-14 Ajinomoto Co., Inc. Method for recovering L-phenylalanine
US5831118A (en) * 1996-06-18 1998-11-03 Katayama Seiyakusyo Co., Ltd. Epimerization of 2- or 4- substituted cyclohexanecarboxylic acids
KR100343062B1 (ko) * 1996-11-15 2002-07-02 에가시라 구니오 정제 조성물
US20040176457A1 (en) * 2003-02-27 2004-09-09 Hemmingsen Lisbeth Tofte Novel NIDDM regimen
ATE249421T1 (de) 1997-06-23 2003-09-15 Tanabe Seiyaku Co Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
RU2280447C2 (ru) * 1999-09-17 2006-07-27 Новартис Аг Способ лечения нарушений метаболизма, прежде всего диабета или заболеваний или состояний, связанных с диабетом
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DK1741446T3 (da) 2000-01-21 2008-06-02 Novartis Pharma Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
AU4116801A (en) * 2000-03-17 2001-09-24 Ajinomoto Kk Drugs for complications of diabetes and neuropathy and utilization thereof
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
WO2002032853A1 (en) 2000-10-18 2002-04-25 Ajinomoto Co.,Inc. Process for the preparation of acylphenylalanines
MXPA03003484A (es) 2000-10-18 2003-07-14 Ajinomoto Kk Procedimiento para producir cristales de nateglinida.
ATE370115T1 (de) * 2000-10-24 2007-09-15 Ajinomoto Kk Verfahren zur herstellung der b-form von nateglinid-kristallen
WO2002040010A1 (fr) * 2000-10-24 2002-05-23 Ajinomoto Co.,Inc. Preparations de medicament contenant du nateglinide
US6740776B2 (en) 2001-07-16 2004-05-25 Novartis Ag Air oxidation of an aromatic aldehyde to an aromatic acid
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
JP2005519949A (ja) * 2002-03-11 2005-07-07 ノバルティス アクチエンゲゼルシャフト ナテグリニドの塩
EP1497258A1 (en) * 2002-04-15 2005-01-19 Novartis AG Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
EP2261202A1 (en) * 2002-04-15 2010-12-15 Ajinomoto Co., Inc. New nateglinide crystals
CN100363332C (zh) * 2002-04-26 2008-01-23 中国人民解放军军事医学科学院毒物药物研究所 芳香性氨基酸衍生物，其制备方法及其医药用途
RU2324676C2 (ru) * 2002-04-29 2008-05-20 Байокон Лимитид Кристаллический n-(транс-4-изопропилциклогексилкарбонил)-d-фенилаланин формы с для лечения сахарного диабета типа 2 и способ его получения
JP4137053B2 (ja) * 2002-04-29 2008-08-20 バイオコン・リミテッド 新規形態のｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニン
US20050096367A1 (en) * 2002-05-28 2005-05-05 Yoshiro Kitahara Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
ES2359910T3 (es) * 2002-05-28 2011-05-30 Ajinomoto Co., Inc. Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso.
US6861553B2 (en) * 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
AU2003256454A1 (en) * 2002-07-03 2004-01-23 Teva Pharmaceutical Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7148376B2 (en) * 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) * 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
WO2004009532A1 (en) * 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20060154970A1 (en) * 2003-01-28 2006-07-13 Yushe Yang Alanines compounds, method of preparing them and their use
JPWO2004074330A1 (ja) * 2003-02-18 2006-06-01 コニシ株式会社 硬化性樹脂、その製造方法及び硬化性樹脂組成物
HU227073B1 (hu) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
JP2007505059A (ja) * 2003-09-11 2007-03-08 ゾルファイ フルーオル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎ−アシル化合物の製造
JP5395327B2 (ja) 2003-09-17 2014-01-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 機構ベースの標的化した膵臓β細胞画像化および治療
KR20080086937A (ko) * 2004-05-07 2008-09-26 테바 파마슈티컬 인더스트리즈 리미티드 나테글리나이드의 다형태
GB0413084D0 (en) * 2004-06-11 2004-07-14 Cipla Ltd Process
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CN101309689B (zh) 2005-09-14 2012-10-10 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
US20070167525A1 (en) * 2005-11-07 2007-07-19 Geesaman Bard J Combinations of metformin and a meglitinide
US7615649B2 (en) * 2006-01-26 2009-11-10 Iowa State University Research Foundation, Inc, Synthesis of polycyclic procyanidins
CN101415668B (zh) * 2006-03-31 2013-06-19 味之素株式会社 羧酸酰氯化合物的制造方法
WO2007113650A2 (en) * 2006-04-05 2007-10-11 Cadila Pharmaceuticals Limited A novel and improved process fro the preparation of nateglinide and its polymorph form-h
CN100383114C (zh) * 2006-07-21 2008-04-23 杭州保灵有限公司 一种那格列奈的制备工艺
WO2009137082A1 (en) * 2008-05-08 2009-11-12 Concert Pharmaceuticals, Inc. 4-isopropylcyclohexylcarbonyl amino acid derivatives
CN102803217B (zh) 2009-05-15 2015-06-17 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基吡啶
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
JP5654608B2 (ja) 2009-11-17 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
AU2011266820A1 (en) * 2010-06-14 2013-01-24 Cipla Limited A process for the preparation of nateglinide
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
WO2013066277A1 (en) 2011-11-03 2013-05-10 Mahmut Bilgic Synergic compositions
WO2013077819A1 (en) 2011-11-23 2013-05-30 Mahmut Bilgic Pharmaceutical formulations comprising nateglinide
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EA028583B1 (ru) 2013-02-14 2017-12-29 Новартис Аг Замещенные бис-фенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
ES2634675T3 (es) 2015-05-20 2017-09-28 Corghi S.P.A. Máquina de equilibrado
JP6720512B2 (ja) * 2015-11-27 2020-07-08 住友化学株式会社 トランス−シクロヘキサンカルボン酸の製造方法
CN108602758B (zh) 2016-02-05 2021-01-26 斯福瑞股份公司 制备反式-4-氨基-1-环己烷基羧酸及其衍生物的方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
DE3382112D1 (de) * 1982-04-30 1991-02-21 Ajinomoto Kk Pharmazeutische zusammensetzung.
JPS58189121A (ja) * 1982-04-30 1983-11-04 Ajinomoto Co Inc インシユリン投与賦活剤

Also Published As

Publication number Publication date
EP0196222A2 (en) 1986-10-01
DE3683662D1 (de) 1992-03-12
JPS6354321A (ja) 1988-03-08
JPH0415221B2 (enExample) 1992-03-17
USRE34878E (en) 1995-03-14
DE10199054I1 (de) 2002-01-10
EP0196222A3 (en) 1988-02-24
EP0196222B1 (en) 1992-01-29
US4816484A (en) 1989-03-28

Similar Documents

Publication Publication Date Title
DE10199054I2 (de) Hypoglycenisches Agens
DE122006000056I2 (de) 2-Fluorarabinofuranosylpurinnukleoside
DK580186A (da) Calcitoninderivater
DK153042C (da) Kaeledyrsfoder
NO171226C (no) Toeymykningsmiddel
DK312586A (da) Furosemidsalte
DK157319C (da) Oxadiazolylimidazobenzodiazepinderivater
DK271786A (da) Motor-kompressor-aggregat
ATA155686A (de) Giesspfannenkopf
FI854688A0 (fi) Polyamidhaltig maongskiktsfilm
BR8605218A (pt) Turbo-alimentador
FI864092A7 (fi) Bruksvagn foersedd med frigoerningsanordning
DK214386D0 (da) Rioprostil-pvp-kompleks
DK164026C (da) Blikdaase
BR8605651A (pt) Torcimetro
DD271637A3 (de) Hochspannungskabelendverschluss
KR870007824U (ko) 아이젠
ES291217Y (es) Medalla-cortante
IT206242Z2 (it) Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
DE3660544D1 (de) 2-hydroxybenzamides
DK160137C (da) Roerboejle-haandspaendesav
ES286591Y (es) Isopresor tubo-timpanico
BR6500981U (pt) Girandola
KR870008596U (ko) 큐풀러
DD284128A7 (de) Auskleidngsmasse